Acquisition Background RMI was acquired by Senzime in 2022 for $44M, indicating a recent exit and potential continuity of the ExSpiron technology under a larger clinical portfolio. This history highlights an opportunity to approach Senzime or successor entities about expansion, integration, and cross-sell of respiratory monitoring capabilities.

Market Leadership Positioned as a global leader in minute ventilation monitoring across patient populations, ExSpiron offers continuous noninvasive respiratory data that complements oxygen saturation monitoring. This niche can be leveraged to pursue hospitals and clinics aiming to enhance early detection of ventilatory distress and reduce care costs.

Regulatory Footprint FDA clearance and CE Mark for ExSpiron support adoption in diverse markets and care settings. Sales opportunities exist in infection control, post-acute care, emergency departments, and perioperative monitoring where validated continuous ventilation data drives decision-making.

Growth Signals Revenue range and a substantial funding base (over a decade of development with funding of $34M) suggest a scalable product with room for deployment in larger health systems, multi-site hospitals, and potential bundled offerings with broader respiratory care solutions.

Strategic Partnerships Past leadership appointments and board activity indicate an active network in medical advisory and investor ecosystems. Targeted outreach to strategic partners, hospital procurement teams, and durable clinical champions could accelerate pilot programs and broader adoption of ExSpiron.